Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer

<div>Kaplan-Meier plot of progression-free survival. The two-year progression-free survival rate of patients treated with weekly cisplatin-based chemotherapy in postoperative CCRT is 70.9%.</div>

BioMed Research International

fig1

Figure 1

Figure 1: Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer 

Figure 1 | Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer 